» Articles » PMID: 37061516

The Specific Core Fucose-binding Lectin Pholiota Squarrosa Lectin (PhoSL) Inhibits Hepatitis B Virus Infection in Vitro

Overview
Journal Sci Rep
Specialty Science
Date 2023 Apr 15
PMID 37061516
Authors
Affiliations
Soon will be listed here.
Abstract

Glycosylation of proteins and lipids in viruses and their host cells is important for viral infection and is a target for antiviral therapy. Hepatitis B virus (HBV) is a major pathogen that causes acute and chronic hepatitis; it cannot be cured because of the persistence of its covalently closed circular DNA (cccDNA) in hepatocytes. Here we found that Pholiota squarrosa lectin (PhoSL), a lectin that specifically binds core fucose, bound to HBV particles and inhibited HBV infection of a modified human HepG2 cell line, HepG2-hNTCP-C4, that expresses an HBV receptor, sodium taurocholate cotransporting polypeptide. Knockout of fucosyltransferase 8, the enzyme responsible for core fucosylation and that aids receptor endocytosis, in HepG2-hNTCP-C4 cells reduced HBV infectivity, and PhoSL facilitated that reduction. PhoSL also blocked the activity of epidermal growth factor receptor, which usually enhances HBV infection. HBV particles bound to fluorescently labeled PhoSL internalized into HepG2-hNTCP-C4 cells, suggesting that PhoSL might inhibit HBV infection after internalization. As PhoSL reduced the formation of HBV cccDNA, a marker of chronic HBV infection, we suggest that PhoSL could impair processes from internalization to cccDNA formation. Our finding could lead to the development of new anti-HBV agents.

Citing Articles

Clinicopathologic significance of FUT8, STX4, and calpain2 expression in ovarian cancer.

Yang Y, Wang M, Chen L, Chen X, Wang Y, Ye W Am J Transl Res. 2025; 17(1):144-161.

PMID: 39959200 PMC: 11826196. DOI: 10.62347/SQKL1957.

References
1.
Liang T, Block T, McMahon B, Ghany M, Urban S, Guo J . Present and future therapies of hepatitis B: From discovery to cure. Hepatology. 2015; 62(6):1893-908. PMC: 4681668. DOI: 10.1002/hep.28025. View

2.
Takamatsu S, Shimomura M, Kamada Y, Maeda H, Sobajima T, Hikita H . Core-fucosylation plays a pivotal role in hepatitis B pseudo virus infection: a possible implication for HBV glycotherapy. Glycobiology. 2016; 26(11):1180-1189. DOI: 10.1093/glycob/cww067. View

3.
Skelly J, Howard C, Zuckerman A . Analysis of hepatitis B surface antigen components solubilized with Triton X-100. J Gen Virol. 1979; 44(3):679-89. DOI: 10.1099/0022-1317-44-3-679. View

4.
Lotfi H, Sheervalilou R, Zarghami N . An update of the recombinant protein expression systems of Cyanovirin-N and challenges of preclinical development. Bioimpacts. 2018; 8(2):139-151. PMC: 6026528. DOI: 10.15171/bi.2018.16. View

5.
Dey B, Lerner D, Lusso P, Boyd M, Elder J, BERGER E . Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J Virol. 2000; 74(10):4562-9. PMC: 111976. DOI: 10.1128/jvi.74.10.4562-4569.2000. View